Conatus
Pharmaceuticals Inc. (Nasdaq: CNAT) reported upbeat results from a Phase 2
clinical trial of emricasan in patients with nonalcoholic fatty liver
disease. The stock price surged $1.58 to $7.34.
Conatus reports upbeat study results
March 26, 2015 at 13:18 PM EDT
